- Market Realist•15 minutes ago
Based on the recommendations of 27 brokerage firms in a Bloomberg survey, 57.7% of analysts gave Pfizer (PFE) a “buy” recommendation while 42.3% analysts rated the company a “hold.” None of the analysts ...
- Market Realist•16 minutes ago
Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.
- Market Realist•3 days ago
Analysts expect a fall of ~0.6% in Novartis’s (NVS) 3Q16 revenue to $12.2 billion following the effects of its product acquisitions and divestitures.
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||74.88 x 11500|
|Ask||74.95 x 7000|
|Day's Range||75.05 - 75.61|
|52wk Range||69.90 - 93.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||26.97|
|Avg Vol (3m)||1,639,696|
|Dividend & Yield||2.72 (3.60%)|